Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler in Subjects With Asthma
Cumulative Dose, 2-Way Crossover Study of the Safety and Efficacy of Albuterol Administered by the Halix™ Dry Powder Inhaler Compared With MDI in Subjects With Asthma
Sponsor: Concentrx Pharmaceuticals, Inc.
Listed as NCT03643874, this PHASE2 trial focuses on Asthma and remains completed. Sponsored by Concentrx Pharmaceuticals, Inc., it has been updated 6 times since 2018, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Completed PHASE2
-
Jul 2024 — Sep 2024 [monthly]
Completed PHASE2
-
Jan 2021 — Jul 2024 [monthly]
Completed PHASE2
-
Feb 2019 — Jan 2021 [monthly]
Completed PHASE2
Status: Recruiting → Completed
-
Nov 2018 — Feb 2019 [monthly]
Recruiting PHASE2
▶ Show 1 earlier version
-
Sep 2018 — Nov 2018 [monthly]
Recruiting PHASE2
First recorded
Jun 2018
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Concentrx Pharmaceuticals, Inc.
- Kramer Consulting, LLC
- PharPoint Research, Inc.
For direct contact, visit the study record on ClinicalTrials.gov .